Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

  • 3 views
  • 18 Jun, 2022
  • 1 location
Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)

dosing schedule is defined, the following patients with BRAF, KRAS and/or NRAS mutations will be enrolled: 26 patients with solid tumours (Parts IIA & IIC) and 10 patients with Multiple Myeloma (Part

platelet count
NRAS
bone marrow procedure
everolimus
lung cancer
  • 33 views
  • 12 May, 2022
  • 2 locations
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines (poorly

granulocyte-macrophage colony-stimulating factor
investigational drug
mek inhibitor
progressive disease
ki-ras
  • 19 views
  • 04 Oct, 2022
  • 1 location
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor mutation status. Patients with RAS mutant and BRAF wild type will be randomised between modified FOLFOXIRI (mFOLFOXIRI

  • 0 views
  • 07 Oct, 2021
  • 1 location
  • 0 views
  • 21 Oct, 2022
  • 19 locations
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

/ alteration whose disease progressed on prior immunotherapy and/or BRAF-targeting therapy.

  • 14 views
  • 04 Feb, 2022
  • 1 location
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)

The association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR-moAbs (panitumumab or cetuximab) is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC

  • 0 views
  • 04 Oct, 2022
  • 1 location
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking

  • 0 views
  • 04 Oct, 2022
  • 4 locations
  • 0 views
  • 14 May, 2021
  • 1 location
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS

medicines (called binimetinib and cetuximab) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and

brain tumor
BRAF
primary brain tumors
cancer
cetuximab
  • 0 views
  • 21 Oct, 2022
  • 2 locations